Abstract:Although the robust antidepressant effects of the N -methyl- d -aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although ( R )-ketamine is a less potent NMDAR antagonist than ( S )-ketamine, ( R )-ketamine has shown more marked and longer-lasting antidepressant-like effects than ( S )-ketamine in several animal models of depression. Furthermore, non-ketamine NMDAR antagonists do not exhibit robust ketamine-like antidepressant effects in patients with depression. These findings suggest that mechanisms other than NMDAR inhibition play a key role in the antidepressant effects of ketamine. Duman’s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine. However, we reported that mTORC1 serves a role in the antidepressant effects of ( S )-ketamine, but not of ( R )-ketamine, and that extracellular signal-regulated kinase possibly underlie the antidepressant effects of ( R )-ketamine. Several lines of evidence have demonstrated that brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), are crucial in the antidepressant effects of ketamine and its two enantiomers, ( R )-ketamine and ( S )-ketamine, in rodents. In addition, (2 R ,6 R )-hydroxynormetamine [a metabolite of ( R )-ketamine] and ( S )-norketamine [a metabolite of ( S )-ketamine] have been shown to exhibit antidepressant-like effects on rodents through the BDNF–TrkB cascade. In this review, we discuss recent findings on the molecular and cellular mechanisms underlying the antidepressant effects of enantiomers of ketamine and its metabolites. It may be time to reconsider the hypothesis of NMDAR inhibition and the subsequent AMPAR activation in the antidepressant effects of ketamine.

Mechanisms of ketamine action as an antidepressant

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Uncovering the Underlying Mechanisms of Ketamine As a Novel Antidepressant

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

NMDA antagonist treatment of depression

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions

A Multiscale View of the Mechanisms Underlying Ketamine’s Antidepressant Effects: An Update on Neuronal Calcium Signaling

Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action

Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels

Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions

The N-methyl-d-aspartate receptor hypothesis of ketamine's antidepressant action: evidence and controversies

The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug

The Role of NMDARs in the Anesthetic and Antidepressant Effects of Ketamine.

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms